GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE

Clinical trials for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE explained in plain language.

Never miss a new study

Get alerted when new GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE trials appear

Sign up with your email to follow new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 2 Not yet finished but already full! 1

New hope for fighting aggressive brain tumors

Disease control Recruiting now

This study is testing a new drug called Debio 0123 for adults with glioblastoma, a fast-growing brain cancer. The goal is to see if adding this drug to standard chemotherapy (temozolomide) and radiation is safe and can help control the cancer better. The research will first find …

Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE

Phase: PHASE1, PHASE2 • Sponsor: Debiopharm International SA • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE

Get alerted when new GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE trials appear

New hope for fighting aggressive brain tumors